Related Experiment Videos
Summary
Human fibrinolysin (plasmin) effectively dissolves blood clots and prevents adhesions. Aerosol administration improved outcomes for premature infants with pulmonary hyaline membrane disease.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Fibrinolytic activity assessment is crucial for therapeutic applications.
- Existing methods for measuring fibrinolysis vary in accuracy and utility.
- Human fibrinolysin (plasmin) holds potential for treating clot-related conditions and adhesion formation.
Purpose of the Study:
- To evaluate methods for determining fibrinolytic activity.
- To assess the efficacy of human fibrinolysin in vivo and in vitro.
- To investigate the therapeutic potential of plasmin in clinical and animal models.
Main Methods:
- Exploration and comparison of various methods for assessing fibrinolytic activity, including euglobulin fraction assays and whole blood clot lysis.
- Development of an in vivo preparation to observe blood clot lysis using human fibrinolysin.
- Administration of human plasmin via aerosol to premature infants and intravenously/intraperitoneally to animals.
Main Results:
- The euglobulin fraction method on a prepared fibrin clot was identified as the most satisfactory for quantifying administered fibrinolysin.
- Successful lysis of experimental blood clots in autogenous veins was observed in vivo.
- Aerosolized plasmin treatment led to complete recovery in infants with pulmonary hyaline membrane disease, contrasting with a 43% mortality rate in untreated controls.
- Intravenous administration of high-dose fibrinolysin completely prevented peritoneal adhesions in animals, whereas intraperitoneal administration was ineffective.
- Increased peripheral blood fibrinolytic activity correlated with the absence of adhesions in treated animals, with minimal hemorrhagic side effects.
Conclusions:
- The euglobulin fraction on a fibrin clot is a reliable method for assessing fibrinolytic activity.
- Human fibrinolysin (plasmin) demonstrates significant therapeutic potential in dissolving clots and preventing adhesions.
- Plasmin aerosol therapy offers a promising treatment for pulmonary hyaline membrane disease in premature infants.